CD274 and malignant peripheral nerve sheath tumor: In the immune checkpoint category, elevated PD-L1 expression has been observed in MPNST patients [125] and is reported to achieve a complete metabolic response to the PD-1 inhibitor pembrolizumab in a patient with PD-L1–positive metastatic MPNST [126].